Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'The Pharmaceutical Company Outlook to : Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech' returned 5 results - Page 1 of 1  FEATURED RESULTS Animal Biotechnology - Technologies, Markets and Companies European Biotech Industry Guide 2007, 5th Ed Marketing and Sales Organization Best Practices for Biotech ... Success Rates in Biotech - Going The Wrong Way Modified Nucleosides: in Biochemistry, Biotechnology and Med...   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Pharmaceutical Company Outlook to 2014   Datamonitor, Dec 2009, Pages: 121 analysis Biotech molecule type analysis Chapter 6 The Japan Pharma Outlook to 2014 Key findings Overview of Japan Pharma to 2014 Japan Pharma company analysis Japan Pharma launch/core/expiry analysis Pharmaceutical Company Outlook to 2015   Datamonitor, Dec 2010, Pages: 128 analysis Biotech therapy area analysis Biotech molecule type analysis THE JAPAN PHARMA OUTLOOK TO Key findings Overview of Japan Pharma to Japan Pharma prescription sales performance Dealmaking and Industry Outlook: Autoimmune and Inflammatory Diseases   Decision Resources, Inc., July 2009, Pages: 43 . 200 deals: Total deal volume; biobucks; 20 largest deals; Big Biotech, Mid-Size Pharma and Big Pharma deals; most active disease areas; most active companies; top five deals by technology, outlicensing Global Biopharma Outlook 2011   MP Advisors, Jan 2011, Pages: 391 US, EU, Japan and ROW companies – formulated with an aim to facilitate strategic and long term investment decision making of senior management. Outlook-11' has been tailored to deliver more M&A Trends in Pharma   Datamonitor, Oct 2008, Pages: 144 &As targeted primarily cardiovascular-focused companies, 2006-mid-2008 83 Figure 26: Big Pharmas and mid pharmas M&As targeted primarily oncology companies if biotech are included in the analysis by therapy area Results:  First -   Prev -   1 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network